<DOC>
	<DOCNO>NCT01616849</DOCNO>
	<brief_summary>This open-label , uncontrolled , multicenter phase II clinical trial . The purpose study evaluate acute toxicity efficacy cisplatin 5-Fu combine nimotuzumab patient untreated metastatic nasopharyngeal carcinoma .</brief_summary>
	<brief_title>Study Chemotherapy Combined With Nimotuzumab Untreated Metastatic Nasopharyngeal Carcinoma</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Nasopharyngeal Neoplasms</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>Histologic diagnosis nasopharyngeal carcinoma Distance metastasis least 6 month radical treatment Not suitable local treatment , e.g . surgery , TACE At least one measurable lesion Estimate survival ＞3months Range 18～70 year old PS 0~1 WBC count ≥ 4×109/L，Hemoglobin ≥ 100g/L， platelet count ≥ 100×109/L ALT AST ＜ 2.5×ULN、bilirubin ＜ 1.5×ULN 0Serum creatinine ＜ 1.5×ULN Central nervous system metastases Suitable local treatment Second malignancy within 5 year Precious therapy investigational agent Uncontrolled seizure disorder serious neurologic disease ≥ Grade Ш allergic reaction drug include study Clinically significant cardiac respiratory disease Creatinine clearance &lt; 30ml/min Drug alcohol addition Do full capacity civil act Severe complication , active infection Concurrent immunotherapy hormone therapy diseases Pregnancy lactation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>September 2015</verification_date>
</DOC>